Welcome to our dedicated page for Aspira Women's Health SEC filings (Ticker: AWHL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aspira Women's Health Inc. filings document the public-company record for a women's health diagnostics business focused on noninvasive gynecologic disease testing. Recent Form 8-K reports cover executive appointments, laboratory-services agreements, secured borrowing, equity-purchase arrangements, investor-presentation disclosures, and other material events involving the company's common stock and operating relationships.
Proxy materials describe board matters, executive compensation, equity awards, and shareholder voting items. Registration statements and related agreements disclose securities offerings, resale registration matters, common stock terms, filer status, and capital-structure effects. The filing record also includes a Form 12b-25 notice related to timing of the annual report and accounting completion for Aspira's Form 10-K.
Aspira Women’s Health Inc. reported continued operating losses and liquidity pressure for the quarter ended June 30, 2026. Q2 revenue was $2.046 million, down from $2.404 million a year earlier, with a gross profit of $1.131 million. Total operating expenses were $2.966 million, leading to a loss from operations of $1.835 million.
Including a $0.485 million loss from remeasuring warrant liabilities and net interest expense, Q2 net loss was $2.420 million (basic and diluted loss per share $0.05). For the first six months of 2026, revenue fell to $4.013 million from $4.683 million, but net loss narrowed to $1.744 million from $4.519 million, helped by a $2.625 million non‑cash gain from warrant revaluation.
Cash and cash equivalents declined to $0.477 million at June 30, 2026, with net cash used in operating activities of $2.369 million in the first half. Management disclosed a working capital deficit of about $2.542 million and an accumulated deficit of about $545.9 million, concluding there is substantial doubt about the company’s ability to continue as a going concern within one year. To support liquidity, Aspira completed a $1.41 million June 2026 private placement, utilized its Lincoln Park equity line, and relies on OvaSuite product sales as its primary recurring cash source.
Aspira Women's Health Inc. reported that Chief Financial Officer John Strahley received a corrected grant of 70,000 employee stock options to buy common stock at an exercise price of $0.50 per share, expiring June 16, 2036. 17,500 options vest on July 26, 2026, with the remaining shares vesting in equal monthly installments over the following nine months.
Aspira Women's Health Inc. reported that Chief Financial Officer John Strahley received a grant of employee stock options for 75,000 shares of common stock on June 16, 2026. The options have a $0.50 exercise price and expire on June 16, 2036. According to the vesting schedule, 18,750 options vest on July 26, 2026, with the remaining options vesting in equal monthly installments over the following nine months. No open-market purchases or sales were reported.
Aspira Women’s Health Inc. entered into a Subordinated Business Loan and Security Agreement with Agile Lending, LLC as lead lender and Agile Capital Funding, LLC as collateral agent. The agreement provides a secured term loan documented by a Subordinated Secured Promissory Note dated as of July 1, 2026.
The Note was issued in a principal amount of $1,050,000, carries scheduled interest charges of $441,000 assuming timely payments, and is scheduled to mature on January 26, 2027. Payment under the Note is expressly subordinated to all Senior Indebtedness. The company and certain subsidiary co‑borrowers granted a continuing security interest in substantially all of their personal property, including goods, accounts, equipment, inventory, general intangibles (including intellectual property), instruments, chattel paper, deposit accounts, other investment property, and related proceeds, subject to customary exclusions. A financing statement may be filed only upon an event of default.
Aspira plans to use the term loan proceeds to refinance debt from a loan received in January and for general corporate purposes. The agreement contains customary affirmative and negative covenants, with certain financial covenant requirements waived, and specifies events of default such as payment failures, covenant breaches, material adverse changes, specified liens, judgments, and insolvency events. Upon default, lenders may accelerate obligations and exercise remedies, including repossession of collateral. The agreement is governed by Virginia law with exclusive jurisdiction in Virginia courts.
Aspira Women's Health Inc. filed a Form 3 identifying John Strahley as Chief Financial Officer and a reporting person under SEC insider rules. The structured data shows no share transactions (0 buys, 0 sells) and zero holding entries, functioning as an administrative insider registration.
Aspira Women’s Health Inc. filed an amended report detailing the separation terms for former Chief Executive Officer Michael Buhle, who ceased serving as CEO effective June 17, 2026. The company and Mr. Buhle entered into a Separation Agreement and General Release on June 27, 2026, which becomes effective after a seven-day revocation period.
Under the agreement, Mr. Buhle will receive cash severance of $200,000, equal to six months of base salary, paid in installments, plus company-paid COBRA health and dental premiums for six months. The company will also accelerate vesting of stock options for 64,583 shares at an exercise price of $0.07 per share, exercisable for 90 days after the effective date, while all other unvested awards are forfeited.
Any shares from these options are subject to a 90-day lock-up from each exercise, a daily sale cap of 2,500 shares, a minimum sale price of $0.45 per share, and broker and notice requirements. The agreement includes mutual releases, non-disparagement, confidentiality, and continued restrictive covenants, and the company reiterates that Mr. Buhle’s departure did not result from any disagreement over operations, policies, or practices.
Aspira Women’s Health Inc. announced a leadership change, with Michael Buhle ceasing to serve as Chief Executive Officer on June 17, 2026. The board appointed its Chairman, John Fraser, as Interim Chief Executive Officer and Principal Executive Officer while it conducts a search of internal and external candidates.
The company states that Mr. Buhle’s departure was not due to any disagreement about operations, policies, or practices. Aspira and Mr. Buhle are discussing a separation agreement, and the company plans to file an amendment disclosing the material terms within four business days after they are determined.
Aspira Women’s Health Inc. reported the results of its 2026 annual stockholder meeting. Of 43,500,411 common shares entitled to vote as of the record date, 27,144,522 shares were represented, a quorum of 62.40%.
Stockholders elected all six director nominees for one‑year terms and approved, on an advisory basis, the compensation of the company’s named executive officers. They also approved an amendment to the 2019 Stock Incentive Plan to add 5,000,000 shares, bringing the total shares authorized under the plan to 9,532,818.
In addition, stockholders ratified the selection of BDO USA, P.C. as the independent registered public accounting firm for the year ending December 31, 2026.
Jack W. Schuler and the Jack W. Schuler Living Trust updated their ownership disclosure in Aspira Women's Health Inc. following a new private purchase. On June 5, 2026, the Trust bought 222,222 shares of common stock and a warrant to purchase 300,000 additional shares under a June 2026 Securities Purchase Agreement.
After this transaction, Mr. Schuler reports beneficial ownership of 4,052,587 shares, or 8.7% of Aspira’s common stock, with most shares held through the Trust. The Trust alone reports 4,046,051 shares, or 8.6% of the company, based on 46,800,411 shares outstanding after including recent issuances.
Aspira Women's Health Inc. insider filing shows net buying activity by the Jack W. Schuler Living Trust, for which Jack W. Schuler serves as sole trustee and may be deemed to beneficially own the securities.
On June 5, 2026, the Living Trust purchased 222,222 shares of Common Stock at $0.45 per share and 300,000 Warrants (Right to Buy) for Common Stock with a $0.75 exercise price expiring in 2029. Following these transactions, the trust held 4,046,051 shares of Common Stock indirectly, while Schuler also held 6,536 Common shares and multiple warrant positions directly and indirectly.